Skip to main content

Table 1 Baseline characteristics of patients in the TACE group and the TACE-RFA group

From: Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

Characteristic TACE group (n = 271) TACE-RFA group
(n = 128)
P value
Sex    0.242
 Male 216 (79.7%) 109 (85.2%)  
 Female 55 (20.3%) 19 (14.8%)  
Age (years)    0.476
 Mean value 56.1 ± 10.8 55.3 ± 10.4  
 Range 28–79 16–83  
Albumin g/dL 37.8 ± 4.9 38.0 ± 5.9 0.692
Total bilirubin u mol/L 20.1 ± 17.5 24.0 ± 54.4 0 0.435
Alpha-fetoprotein level    0.443
  < =400 ng/mL 180 (66.4%) 80 (62.5%)  
  > 400 ng/mL 91 (33.6%) 48 (37.5%)  
Child-Pugh score    0.676
 A 239 (88.2%) 111 (86.7%)  
 B 32 (11.8%) 17 (13.3%)  
BCLC stage    0.000
 A 110 (40.6%) 88 (68.8%)  
 B 161 (59.4%) 40 (31.2%)  
Liver disease type    0.504
 Hepatitis B 242 (89.3%) 109 (85.2%)  
 Hepatitis C 9 (3.3%) 6 (4.7%)  
 Other 20 (7.4%) 13 (10.2%)  
Mean tumor diameter (cm) 6.8 ± 4.3 4.5 ± 3.1 0.000
Tumor diameter range (cm)    0.000
  < =3.0 70 (25.8%) 50 (39.1%)  
 3.1–5.0 50 (18.5%) 40 (31.2%)  
 5.1–10.0 89 (32.8%) 27 (21.1%)  
  > 10 62 (22.9%) 11 (8.6%)  
Number of tumors    0.102
 1 201 (74.2%) 102 (79.7%)  
 2 49 (18.1%) 23 (18.0%)  
 3 21 (7.7%) 3 (2.3%)  
  1. BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization